Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04118166 · ClinicalTrials.gov registry record · Phase 2

Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma

A Phase 2 study of Soft Tissue Sarcoma, sponsored by Kristen Ganjoo.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT04118166: Completed Phase 2 study of Soft Tissue Sarcoma, sponsored by Kristen Ganjoo.

NCT04118166 is a Phase 2 study of Soft Tissue Sarcoma that has completed, run by Kristen Ganjoo. The registered enrollment target is 30 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04118166, a Phase 2 study of Soft Tissue Sarcoma, has completed, sponsored by Kristen Ganjoo.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this Phase 2 study is to 1. find out if the study drugs (ipilimumab plus nivolumab) in combination with cryotherapy will help participants with metastatic or locally advanced soft tissue sarcoma;. 2. find out how safe are ipilimumab plus nivolumab given in combination with cryotherapy, and what side effects may be related to treatment. 3. find out how do the study drugs in combination with cryotherapy work in soft tissue sarcoma.

Primary Outcome

Clinical benefit was assessed on the basis of clinical response per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria: * Complete response (CR) = Disappearance of all target lesions; all lymph nodes \< 10 mm on the short axis; no new lesions. * Partial response (PR) = ≥ 30% decrease in the sum of the longest diameter of target lesions; no new lesions. * Stable disease (SD) = Small changes that do not meet any of the above criteria; no new lesions. * Progressive disease (PD

Conditions Studied

Soft Tissue Sarcoma

Interventions

  • DRUG Nivolumab
  • DRUG Ipilimumab
  • PROCEDURE Cryoablation

Study Locations (1)

California

  • Stanford Medical Center - Stanford

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-10-01
Est. Completion 2022-04-26
Phase Phase 2
Kristen Ganjoo

2 total trials

What the finished NCT04118166 record still lists

NCT04118166 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (62% lower).

The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT04118166 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04118166 about?

NCT04118166 is a clinical study titled "Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma". The purpose of this Phase 2 study is to 1. find out if the study drugs (ipilimumab plus nivolumab) in combination with cryotherapy will help participants with metastatic or locally advanced soft tissue sarcoma;. 2. find out how safe are ipilimumab plus nivolumab given in combination with cryotherap...

What is the current status of trial NCT04118166?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-10-01. Estimated completion is 2022-04-26.

What conditions does trial NCT04118166 study?

This clinical trial studies the following conditions: Soft Tissue Sarcoma.

What interventions are being tested in trial NCT04118166?

The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Cryoablation (PROCEDURE).

Who is sponsoring clinical trial NCT04118166?

This trial is sponsored by Kristen Ganjoo, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04118166 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Soft Tissue Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04118166's enrollment target sits among peer trials

30 34th of 55 higher than 17 of 55 other Soft Tissue Sarcoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04118166, the US trial registry maintained by the National Library of Medicine. NCT04118166 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.